RSV

 
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
February 14, 2025

Your daily dose of the clinical news you may have missed.

COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
February 03, 2025

Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.

Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
January 30, 2025

The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
October 29, 2024

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions
October 23, 2024

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

Respiratory Syncytial Virus: A Year of Infant Protection Breakthroughs
December 12, 2023

The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.

Pfizer Wins FDA Approval for Vaccine against RSV in Older Adults
June 01, 2023

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Adult RSV Vaccine: How Will Older Adults React to New Kid on the Block?
May 31, 2023

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

Robust RSV Surveillance Data Will be Key to Getting US Clinicians Comfortable with New Adult Vaccine
May 26, 2023

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Are US Seniors Ready for an RSV Vaccine? Consider the Lessons of COVID-19, says Dr Kelly Moore
May 23, 2023

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.